There were 240 press releases posted in the last 24 hours and 170,908 in the last 365 days.

Clearside Biomedical, Inc. to Report Second Quarter 2017 Financial Results on August 9, 2017 – Conference Call to Follow

/EIN News/ -- ALPHARETTA, Ga., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD) (“Clearside” or the “Company”), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, announced today that its second quarter 2017 financial results will be released at approximately 7:00 a.m. ET on Wednesday, August 9, 2017. Following the release, Clearside will host a live conference call and webcast at 8:30 a.m. ET to discuss the Company’s financial results and provide a general business and strategic review.

The live webcast and a replay may be accessed by visiting the “Investor Relations” section at www.clearsidebio.com. Alternately, please call (844) 263-8310 (U.S.) or (213) 358-0959 (international) to participate in the live conference call. The conference ID number for the live call is 65348144. Please dial in approximately 10 minutes prior to the call. An archive of the webcast will be available until September 10, 2017.

About Clearside Biomedical, Inc.

Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a late-stage clinical ophthalmic biopharmaceutical company that envisions a world without blindness.  Clearside relentlessly pursues transformative, elegant, precise solutions to restore and preserve vision. Clearside is developing advanced clinical and preclinical product candidates using a proprietary treatment approach offering unprecedented access to the back of the eye through the suprachoroidal space (SCS™). This offers potentially meaningful treatment benefit to patients suffering from sight threatening diseases like uveitis, retinal vein occlusion, diabetic macular edema and wet age-related macular degeneration. To learn more about how Clearside is changing ophthalmology, please visit us at www.clearsidebio.com.

Contacts:

Stephen Kilmer
Investor Relations
678-430-8206
stephen.kilmer@clearsidebio.com

Charles Deignan
Chief Financial Officer
678-270-4005
charlie.deignan@clearsidebio.com

Primary Logo

Distribution channels: Technology